A. Most cases of hemophilia are due to Factor VIX deficiency (hemophilia B). B. Hemophilia is an X-linked congenital bleeding disorder. C. Hemophilia A and B, upon physical examination, are indistinguishable. D. Severe hemophilia is defined as a clotting factor concentration of less than 1%.

A. Xyntha B. Adynovate C. Eloctate D. NovoEight

A. Inhibitor-bypassing agents are administered primarily in the pharmacy clinic. B. Patients can reconstitute and administer inhibitor bypassing agents as long as they have undergone education on sterile techniques. C. Patients with hemophilia B are unable to receive inhibitor-bypassing therapy. D. Patients taking inhibitor-bypassing agents do not need to contact their hemophilia treatment center healthcare providers if they suspect they have had a bleeding episode.

A. Ask his doctor to switch him to Fc fusion factor replacement therapy, because they are associated with a lower risk of inhibitor development. B. Stay with his current therapy because PEGylated factor replacement therapies are less expensive and dosed less frequently. C. KG should switch to on-demand therapy. D. Educate KG on the risk of inhibitor development with different types of factor replacement therapies and consult with his prescriber if he has additional concerns.

A. Being knowledgeable B. Being profitable C. Being accessible D. Being safe and thorough